AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06125327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Patients receive the dose of SC1011 tablets orally twice daily (b.i.d) for 52 weeks.
Study NCT06125327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Patients receive the dose of placebo orally twice daily (b.i.d) for 52 weeks.
Study NCT03084952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucantime
Description: Leishmaniasis standard drug in Brazil
Study NCT06411158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interventionist-guided training
Description: Interventionist-guided training at baseline (i.e., approximately 6 weeks postpartum), followed by a Home Exercise Prescription (HEP), a second interventionist-guided training session approximately 4 weeks later, and then continued HEP. Two exercise sets per day are encouraged between baseline and 6 months postpartum (i.e., time of the primary outcome), followed by at least 3 times-per-week exercise sets until 12 months postpartum. Home exercises will be encouraged using a PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
Study NCT06411158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home pelvic floor exercises guided by the leva® device
Description: Home pelvic floor exercises guided by the leva® device and its accompanying app/software for gradually increasing strength and duration of pelvic floor contractions. Between baseline and 6 months postpartum, twice-daily exercise sets will be encouraged, followed by at least 3 times-per-week exercises from 6 to 12 months postpartum. As in Arm 1, the PFDN research smartphone app, resources to help participants with home exercises and prompts for participants to confirm the number of exercise sets completed.
Study NCT06411158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education will be provided on pelvic floor muscle function and continence mechanisms. No specific prescription or verbal direction will be given regarding the suggested number and frequency of home pelvic floor muscle exercises.
Study NCT04656964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam tosilate group
Description: Patients received an initial dose of 0.2mg/kg of remimazolam tosilate(plus repeated 2.5 mg top-ups doses to a total of up to 12.5mg within 15 minutes).
Study NCT04656964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam group
Description: Patients received an initial dose of 0.03mg/kg of midazolam(One additional dose of 0.015 mg / kg midazolam was allowed).
Study NCT05942040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored Palliative Care Information
Description: This study test feasibility and acceptability of implementing tailored informational materials into clinician's discussions about CBPC with MA plan members who are eligible for the service.
Study NCT05059574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Crawling
Description: The mother's first breast-feeding of her baby is not routine biological breast-feeding, but as a cradle to the breast.
Study NCT06084728 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color Doppler ultrasonography
Description: in a longitudinal plane, the dorsal clitoral artery, which is sampled on the outer surface of the clitoral body as previously described. With the same longitudinal approach, the terminal branch of the posterior labial artery (a branch of the internal pudendal artery) was visualized posterolaterally to the labia majora
Study NCT06515509 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate implant placement with or without loading
Description: immediate implant placement with or without loading
Study NCT06496659 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Segmentectomy
Description: A segmentectomy is a surgical procedure to remove a segment of the lung. This surgery will be done on patients who have completed neoadjuvant therapy for diagnosis of Non-Small Cell Lung Cancer.
Study NCT06006468 — intervention group
Intervention type: GENETIC
Intervention: High genetic risk for type 1 diabetes
Description: in individuals without diabetes comparison of prevalence of islet auto antibodies between individuals at high genetic risk of type 1 diabetes versus controls
Study NCT06006468 — intervention group
Intervention type: GENETIC
Intervention: High gentic risk for Coeliac disease
Description: in individuals without Coeliac disease comparison of prevalence of anti tissue transglutaminase antibodies between individuals at high genetic risk of coeliac disease versus controls
Study NCT06106984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Graded motor imagery mobile app
Description: The Graded Motor Imagery mobile app is a mobile app designed for intervention in phantom limb pain.
Study NCT06164756 — intervention group
Intervention type: OTHER
Intervention: Cognitive Behavior Therapy (CBT)
Description: Participants will receive 10 weeks of CBT
Study NCT06164756 — intervention group
Intervention type: OTHER
Intervention: Treatment As Usual (TAU)
Description: Participants will receive standard of care treatment
Study NCT05431088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osivelotor
Description: Tablets which contain drug substance
Study NCT05431088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Osivelotor
Description: Tablets which contain drug substance
Study NCT05431088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: Tablets which contain drug substance
Study NCT06313957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LUCAR-20SP cells
Description: Prior to infusion of the LUCAR-20SP, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine.
Study NCT05773586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-5918
Description: oral tablets 10mg, 50mg.
Study NCT05773586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo
Study NCT06163807 — intervention group
Intervention type: DRUG
Intervention: Antiasthmatic
Description: real-life
Study NCT05544929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KFA115
Description: Immunomodulatory agent
Study NCT05544929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 antibody
Study NCT05623514 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trans-vaginal ultrasound
Description: Pre-operative trans-vaginal ultrasound in order to evaluate sliding sign between the uterus and the rectum
Study NCT06643962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax in the EPBCRlow cohort will be added to the ongoing 3+7 regimen. In the first induction cycle: venetoclax needs to be ramped up: 100 mg on day 5, 200mg on day 6, and 400mg on days 7-14, orally once daily. In the second induction (if required), venetoclax 400mg will be administered orally once daily on days 5-14 without a dose ramp-up schedule. Venetoclax in the EPBCRlow cohort during consolidation therapy: 400mg on days 1-7, orally once daily, along with the consolidation chemotherapy.
Study NCT06643962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubincin
Description: Idarubicin (IDA): 10mg/m\^2/d (age \<60 years old) or 6mg/m\^2/d on days 1-3, intravenously (IV).
Study NCT06643962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: During induction therapy: 100mg/m2/d on days 1-7, IV. During consolidation therapy: intermediate-dose cytarabine for age >55 years old: 1.0g/m\^2 q12h on days 1-3, high-dose cytarabine for age ≦55 years old: 2g/m2 q12h on days 1-3.
Study NCT05996068 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: arterial line
Description: insert arterial line for patients who meet major trauma criteria
Study NCT05025605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 80 Micrograms
Description: Sublingual film containing 80 Micrograms BXCL501
Study NCT05025605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Film
Description: Matching Sublingual Placebo film
Study NCT05025605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 120 Micrograms
Description: Sublingual film containing 120 Micrograms BXCL501
Study NCT05025605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501 60 Micrograms
Description: Sublingual film containing 60 Micrograms BXCL501 Europe Only
Study NCT05649540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05649540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Potassium-competitive acid blocker
Study NCT05649540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05649540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication
Study NCT05625841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey product
Description: Bee products intervention from the first day of radiation to the end of radiation therapy duration 8-12 weeks.
Study NCT06375863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: QT and QTc interval
Description: measuring of QT and QTc on ECG
Study NCT05625841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propolis
Description: propolis
Study NCT05625841 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT05909436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-010
Description: In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W.~In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
Study NCT06062368 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate of Entry
Description: The participant will enter and exit the MRI scan at a slower rate than the manufacturer entry and exit.
Study NCT06146218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contemplative-Based Resilience Training (CBRT)
Description: The intervention is a 10-week program that will address mindfulness, compassion, social-emotional self-care, exposing stress-reactive habits, self-awareness, visualization, and deep breathing. The rationale for applying this mindfulness intervention to promote psychological resilience following the development of race-based traumatic symptoms is based on the notion that mindfulness promotes acceptance of complex thoughts and feelings, reduces rumination, and improves psychological function, cognitive flexibility, and coping processes.
Study NCT04788303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: School meal, garden, education, and community workshops
Description: School meal: midday meal provided at intervention schools~School garden: garden used to grow crops (which will be used to supplement the school meal in the full intervention schools)~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH.
Study NCT04788303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Garden, education, and community workshops
Description: School garden: garden used to grow crops~Education: agriculture, nutrition, and water, sanitation, and hygiene (WASH) curriculum~Community workshops: Led by agricultural extension workers and open to community members, the community workshops will cover nutrition messages, agricultural messages, and hands-on activities on nutrition, agriculture, and WASH.
Study NCT04853667 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interview, lasting a maximum of one hour
Study NCT05492383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: Patients with severe symptomatic AS undergoing Transcatheter aortic valve implantation (TAVI)
Study NCT04704882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: omental patchwork
Description: the omental flaps were sewn to lesser omentum and hepatorenal ligament to cover all the vessels
Study NCT05545813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants will be asked to take 1 capsule (3 billion CFU) daily for 8 weeks in the morning with their first meal.
Study NCT05545813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be asked to take 1 capsule daily for 8 weeks in the morning with their first meal.
Study NCT05413967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mills manipulation in addition to myofasical release therapy
Description: Group A will receive Mills manipulation in addition to myofasical release therapy as baselin
Study NCT05413967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nirschl exercises in addition to myofascial release therapy
Description: Group B will receive Nirschl exercises in addition to myofascial release therapy as baseline
Study NCT04827121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascial iliac compartment block
Description: Patients will recieve supra-inguinal approach of fascial iliac compartment block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
Study NCT04827121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: Patients will recieve transmuscular approach of quadratus lumborum block under ultrasound guidance with 30 ml of 0.5 percent ropivacaine.
Study NCT04990440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab
Description: Participants will receive bermekimab IV.
Study NCT04990440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo IV.
Study NCT06529289 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training
Description: We conducted one day of training for FCHVs and four different groups of FCHVs from two municipalities. We conducted training on hypertension knowledge and blood pressure measurement skills for FCHVs. Studies from Nepal show that with appropriate training, FCHV has the potential to promote hypertension education and conduct hypertension screening. Access to essential equipment such as digital blood pressure monitors, would improve FCHV performance on measuring blood pressure. Therefore, our training was to provide hypertension knowledge and to train FCHVs to measure blood pressure.~The training had two objectives referring to enhancing knowledge and building skills.
Study NCT05293535 — intervention group
Intervention type: OTHER
Intervention: Prognostic study
Description: No intervention... as it is a prognostic study and no intervention done on patients.
Study NCT06401928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of either 1.5 mA electrical stimulation for 20 minutes each day over 10 consecutive days.
Study NCT06401928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation combined with cognitive training
Description: Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on 10 consecutive days. Each session is followed by 30 minutes cognitive training in which patients conduct several computerized cognitive tests.
Study NCT06401928 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of sham (placebo) electrical stimulation for 20 minutes each day over 10 consecutive days.
Study NCT06532019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted intervention based on risk factors
Description: Correct hypoalbuminemia, anemia or hyponatremia, and try to enhance medication to lower NT-proBNP, CRP, NYHA Classification, to add diuretics for patients with higher RADs, multidiscipline intervention for patients complicating COPD, and actively reperfusion for ischemic HFpEF patients.
Study NCT06024577 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: Prescribed 150 minutes per week of moderate to vigorous walking.
Study NCT06024577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variety
Description: Prescribed 150 minutes per week of moderate to vigorous variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training.
Study NCT06024577 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive
Description: Prescribed 150 minutes per week of moderate to vigorous progressive variety of exercise. Each week participants are randomly asked to participate in cycling, walking/jogging, yoga/Pilates, or cross-training. Participants can choose which exercise they want to do, and can do as much or little as they want.
Study NCT06181643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program with Individual Delivery + No Booster Sessions
Description: 4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). No booster sessions.
Study NCT06181643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program with Group Delivery + No Booster Sessions
Description: 4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). No booster sessions.
Study NCT06181643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program with Individual Delivery + 3 Booster Sessions
Description: 4 weekly SSP sessions delivered to individual participants (session durations approximately 45 min/session). 3 monthly booster sessions.
Study NCT06181643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program with Group Delivery + 3 Booster Sessions
Description: 4 weekly SSP sessions delivered to groups of participants (session durations approximately 90 min/session). 3 monthly booster sessions.
Study NCT04861805 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Vienna Aortic Valve SE System
Description: Vienna Aortic Valve SE system for TAVI.
Study NCT04805021 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT06634901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy Educational Session- Comparator
Description: During the pre-to-post-test interval for the Knowledge, Attitudes, and Practices (KAP) measure, participants in this arm will take a break and have lunch.
Study NCT06634901 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Literacy Educational Session
Description: The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
Study NCT06634901 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Literacy Educational Session
Description: The Intervention is a 90 minute small group (n=6-10) session with an expert epilepsy provider reviewing fundamental information about epilepsy being a treatable neurologic condition, with topics including epidemiology, causation facts and myths, treatment and the importance of consistent medication, stigma, barriers to care and well-being. These topics will be covered in the first 45 minutes, leaving the second 45 minutes for Q\&A with the expert. This session provides the basic health information relevant to people with epilepsy, communication of which is often sacrificed in overcrowded clinics found in low resource settings.
Study NCT04632784 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artiflex Presbyopic implantation
Description: Implantation of iris-fixated multifocal Artiflex Presbyopic IOL
Study NCT06489379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high flow nasal cannula
Description: humidified and heated oxygen
Study NCT06489379 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard oxygen
Description: oxygen delivery through Venturi mask
Study NCT06180395 — intervention group
Intervention type: OTHER
Intervention: Group 1
Description: consisted of 37 children with CP classified to level I, II and III according to GMFCS., then:~Dual-energy X-ray absorptiometry (DXA) scans will be used to assess bone mineral density (BMD).~Gross motor function measurement scale (GMFM) will be used to assess gross motor function.~Quality of Life Questionnaire for Children (CP QOL-Child) will be used to assess quality of life (QOL).